Step by Step

INTRODUCTION

ABIM MOC Activity ID

10/2/2018 - Medical Grand Rounds: Modified CRISPR/Cas for Safe and Effective Sickle Gene Correction in Patient Blood Stem Cells

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Appraise patient outcomes using current therapies for sickle cell disease.
  • Outline diagnostic skills for identifying sickle cell disease patients at high risk for morbidity and mortality.
  • Examine patient outcomes through knowledge of current and future potential to refer patients for gene therapy clinical research.

Suggested Additional Reading:

  1. Li C, Ding L, Sun CW, Wu LC, Zhou D, Pawlik KM, Khodadadi-Jamayran A, Westin E, Goldman FD, Townes TM. Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction. Sci Rep. 2016 Jul 27;6:30422. doi: 10.1038/srep30422. PubMed PMID: 27460639; PubMed Central PMCID: PMC4961958.
  2. Chang CW, Lai YS, Westin E, Khodadadi-Jamayran A, Pawlik KM, Lamb LS Jr, Goldman FD, Townes TM. Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting. Cell Rep. 2015 Sep 8;12(10):1668-77. doi: 10.1016/j.celrep.2015.08.013. Epub 2015 Aug 28. PubMed PMID: 26321643.
  3. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nat Rev Dis Primers. 2018 Mar 15;4:18010. doi: 10.1038/nrdp.2018.10. Review. PubMed PMID: 29542687.
  4. Jayavaradhan R, Malik P. Genetic Therapies for Sickle Cell Disease. Pediatr Clin North Am. 2018 Jun;65(3):465-480. doi: 10.1016/j.pcl.2018.01.008. Review. PubMed PMID: 29803277.

Authors:
Gregory Kato, MD — Professor of Medicine, director of the Adult Sickle Cell Center of Excellence for the UPP Division of Hematology-Oncology, and director of the Vascular Medicine Institute/Institute for Transfusion Medicine Sickle Cell Center of Excellence
Dr. Kato receives research support from Bayer. Dr. Kato’s past research support was from AesRx. Dr. Kato is a consult for Bioverativ, Novartis, Global Blood Therapeutics.
Tim M. Townes, PhD — Professor Emeritus Department of Biochemistry and Molecular Genetics Schools of Medicine and Dentistry University of Alabama at Birmingham
Dr. Townes is a stockholder with HemEdits, LLC
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other health care professionals are awarded (0.1) continuing education units (CEU) which are equivalent to 1.0 contact hours.

The University of Pittsburgh is an affirmative action, equal opportunity institution.